Welcome to our dedicated page for Bright Minds Biosciences SEC filings (Ticker: DRUG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.
The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.
Bright Minds Biosciences Inc. filed a Form 6-K attaching its Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024 and its Management's Discussion and Analysis for the second quarter ended March 31, 2025. The filing lists Exhibits 99.1–99.4, including CEO and CFO certifications, and states these interim documents are incorporated by reference into the company’s Form F-3 registration statement (File No. 333-284694). The report is signed by CFO Ryan Cheung and dated August 8, 2025.